Oklahoma Senate Bill SB1551

Oklahoma 2026 Regular Session

• Introduced: 2/2/26
• Refer: 2/3/26

Caption

Pharmaceutical advertising; prohibiting direct-to-consumer advertising; providing administrative penalties. Effective date.

Summary

SB 1551 would create a new section of Oklahoma law prohibiting direct-to-consumer pharmaceutical advertising in the state. The bill defines that term broadly to include promotional communications aimed at consumers through television, radio, print, digital platforms, and social media that market prescription drugs. Under the bill, no person or entity could engage in such advertising in Oklahoma. The State Board of Pharmacy would be authorized to enforce the prohibition by assessing administrative penalties of up to $10,000 per day for each violation, with each day treated as a separate violation. The Board would also be allowed to adopt rules to implement the new law, and the measure would take effect November 1, 2026.

Impact

The bill would add a new prohibition to Title 59 of the Oklahoma Statutes, expanding the State Board of Pharmacy’s regulatory authority over pharmaceutical marketing. It would affect drug manufacturers, advertisers, media outlets, and any other entities involved in consumer-directed prescription drug promotion, while creating a new administrative enforcement mechanism and penalty structure for violations.

Sentiment

There is no recorded committee transcript or vote history provided, so the bill’s sentiment is reflected primarily in its introduction and referral status. The measure appears to be a policy proposal aimed at restricting pharmaceutical marketing, and its referral to the Business and Insurance committee suggests it was still in the early stages of legislative consideration.

Contention

The main point of contention is likely the bill’s broad ban on direct-to-consumer pharmaceutical advertising, which could raise concerns about free speech, commercial speech regulation, and the practical impact on media and pharmaceutical companies. Supporters would likely view it as a consumer-protection and public-health measure, while opponents may argue it is overly restrictive and difficult to enforce. No specific objections or supporters are identified in the available materials.